The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a ...

Bright Uro Inc. secured U.S. FDA 510(k) clearance for the Glean abdominal sensor, which expands the capabilities of its Glean urodynamics system to enable multichannel urodynamic studies. The new ...

Seven years, almost to the day, after releasing a draft guidance on post-approval pregnancy safety studies, the U.S. FDA is now finalizing it – albeit with a few changes.

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Amplitude Vascular Systems, Assertio, Capricor, Garda, GSK, Merck, Nippon, Stryker.

In a deal that could be worth up to $1 billion for Suzhou Siran Biotechnology Co. Ltd. (Siranbio), GSK plc licensed exclusive ...

Biopharma financing activity is continuing its rebound in early 2026 compared to the past several years. Total funding ...

Raising $279 million in an IPO and another $25 million in a concurrent private placement, Odyssey Therapeutics Inc. is ...

Atara Biotherapeutics Inc.’s allogeneic T-cell immunotherapy, Ebvallo (tabelecleucel), for Epstein-Barr virus-positive post-transplant lymphoproliferative disease isn’t out of the running yet. Despite ...

Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash deal worth $4.1 billion. The acquisition ...

Infectious disease-focused biopharma stocks, tracked on the BioWorld Infectious Disease Index (BIDI), saw their collective ...

Reports that Sanofi SA has asked to withdraw its sBLA for Tzield (teplizumab) from the U.S. FDA’s Commissioner’s National ...

Med-tech financing activity in the first four months of 2026 reached $10.05 billion, similar to 2025’s $10.31 billion and ...